Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
11 hedge funds and large institutions have $6.74M invested in Osiris Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 53 closing their positions.
75% less capital invested
Capital invested by funds: $27.5M → $6.74M (-$20.7M)
83% less funds holding
Funds holding: 64 → 11 (-53)
92% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 53
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $139K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$6.19M |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$553K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$152K |
| 4 |
FPF
FNY Partners Fund
New York
|
+$86.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.54M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.45M |
| 3 |
Renaissance Technologies
New York
|
-$2.37M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.41M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.17M |
OSIR Hedge Fund Activity: Q1 2017 in Review
11 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q1 2017, worth a combined $6.74M — down 75% from $27.5M a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of OSIR and 4 opened new positions — a net loss of 49 holders — while 4 trimmed existing stakes and 0 added.
The largest buyer was HealthInvest Partners, opening a new position worth an estimated $6.19M. The largest seller was Vanguard Group, exiting entirely with an estimated $3.54M sold.
- 11 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q1 2017, down from 64 in Q4 2016.
- Funds reported $6.74M of Osiris Therapeutics, Inc. Common Stock stock for Q1 2017, down 75% quarter-over-quarter.
- 4 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q1 2017 and 53 closed out, a net change of -49 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q1 2017 was HealthInvest Partners, an estimated $6.19M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q1 2017 was Vanguard Group, an estimated $3.54M sold.
Based on aggregated 13F filings for Q1 2017.